NCM
KROS icon

Nantahala Capital Management’s Keros Therapeutics KROS Stock Holding History

Nantahala Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Buy
1,410,419
+50,000
+4% +$557K 0.5% 55
2026
Q1 		$15M Buy
1,360,419
+1,000,000
+277% +$15.4M 0.55% 49
2025
Q4 		$7.34M Sell
360,419
-872,770
-71% -$15.3M 0.24% 87
2025
Q3 		$19.5M Sell
1,233,189
-387,503
-24% -$5.72M 0.68% 31
2025
Q2 		$21.6M Buy
1,620,692
+113,902
+8% +$1.54M 0.85% 22
2025
Q1 		$15.4M Buy
1,506,790
+591,742
+65% +$6.87M 0.61% 26
2024
Q4 		$14.5M Buy
915,048
+533,389
+140% +$27.7M 0.62% 35
2024
Q3 		$22.2M Buy
381,659
+2,852
+0.8% +$141K 1.12% 19
2024
Q2 		$17.3M Buy
378,807
+84,810
+29% +$4.56M 1.01% 18
2024
Q1 		$19.5M Sell
293,997
-16,144
-5% -$957K 1.11% 19
2023
Q4 		$12.3M Sell
310,141
-18,640
-6% -$584K 0.74% 25
2023
Q3 		$10.5M Sell
328,781
-168,380
-34% -$6.29M 0.9% 25
2023
Q2 		$20M Sell
497,161
-245,658
-33% -$10.8M 1.93% 10
2023
Q1 		$31.7M Sell
742,819
-49,274
-6% -$2.49M 2.43% 10
2022
Q4 		$38M Sell
792,093
-53,599
-6% -$2.5M 2.47% 9
2022
Q3 		$31.8M Sell
845,692
-66,209
-7% -$2.29M 2.06% 12
2022
Q2 		$25.2M Buy
911,901
+95,071
+12% +$4.17M 1.26% 23
2022
Q1 		$44.4M Buy
816,830
+20,132
+3% +$1.03M 1.97% 14
2021
Q4 		$46.6M Buy
796,698
+36,315
+5% +$1.81M 1.64% 18
2021
Q3 		$30.1M Buy
760,383
+161,503
+27% +$5.75M 0.95% 30
2021
Q2 		$25.4M Buy
598,880
+138,508
+30% +$7.5M 0.72% 33
2021
Q1 		$28.3M Sell
460,372
-74,142
-14% -$4.7M 0.83% 31
2020
Q4 		$37.7M Buy
534,514
+257,687
+93% +$16.2M 1.17% 21
2020
Q3 		$10.7M Buy
276,827
+1,827
+0.7% +$72.5K 0.33% 64
2020
Q2 		$10.3M Buy
+275,000
New +$8.47M 0.31% 61

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Nantahala Capital Management's KROS Position: Q2 2026 in Review

Nantahala Capital Management increased its Keros Therapeutics (KROS) stake by 3.7% in Q2 2026, buying an estimated $557K and bringing the position to 1,410,419 shares worth $15.1M. The position accounts for 0.5% of the portfolio, ranked #55.

Nantahala Capital Management first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $46.6M in Q4 2021. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Nantahala Capital Management held 1,410,419 shares of Keros Therapeutics worth $15.1M as of Q2 2026.
  • Nantahala Capital Management bought 50,000 Keros Therapeutics shares in Q2 2026, an estimated $557K.
  • Keros Therapeutics made up 0.5% of Nantahala Capital Management's portfolio in Q2 2026, its #55 holding.
  • Nantahala Capital Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Nantahala Capital Management's Keros Therapeutics position peaked at $46.6M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.